Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of HSP638DP in moderate-to-severe active thyroid eye disease
CTR20253382Phase 2Active
- Sponsor
- Boyao Biopharmaceutical
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HSP638DP in Graves Orbitopathy (GO) (6 arms), sponsored by Boyao Biopharmaceutical. Primary endpoint: Proptosis responder rate. Started Aug 2025; status: active.
02
Drugs
HSP638DP
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on CTR20253382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253382.